News

The company scaled up manufacturing process for Laccure Pessary product. A search has been started for a company interested in acquiring Laccure and launching the product. Laccure CEO

The European Commission (EC) has granted marketing authorization for Strensiq, which treats the bone manifestation of pediatric-onset hypophosphatasia (HPP). Alexion said HPP is a genetic and progressive metabolic

The company previously received the first part of the award in March 2015 and successfully completed part one. Part two of the Fast-Track SBIR award totals $1.4 million

SGX942 is a first-in-class innate defense regulator (IDR) and is being evaluated as a treatment for oral mucositis in patients undergoing chemoradiation (CRT) therapy for head and neck

UL EduNeering, a leading provider of quality and compliance training solutions for regulated industries, will educate all CDSCO inspectors and regulators with the UL e-learning modules, co-developed and

The company expects to report preliminary top-line data by the end of the fourth quarter of 2015. PINTA 745 is a peptibody that binds myostatin and inhibits its

The clinical trial, dubbed EVEREST, will evaluate the antiviral activity, safety and pharmacokinetics of a combination regimen of Danoprevir (ASC08), a direct-acting antiviral agent and NS3/4A inhibitor, and

The twice-a-day product can be used in adult males for conditions related with a deficiency or absence of endogenous testosterone (hypogonadism). The company’s oral androgen replacement (SOAR) pivotal

Under the terms of the agreement, Bristol-Myers will pay $150m in cash up front for the right to buy Promedior. Bristol-Myers can exercise its right after Promedior completes